Ischemia-reperfusion injury: Assessment and treatment, part II

Journal of Veterinary Emergency and Critical Care

Volumn 14, Issue 4, 2004, Pages 242-252

  McMichael, Maureen ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Glutathione; Hydroxyl radical; Isoprostanes; Lipid peroxidation; Malondialdehyde; Reactive oxygen species; Superoxide

Indexed keywords

ACETYLCYSTEINE; ADENOSINE; ALLOPURINOL; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; ASCORBIC ACID; CALCIUM CHANNEL BLOCKING AGENT; DEFEROXAMINE; DIMETHYL SULFOXIDE; ENDOTHELIN RECEPTOR ANTAGONIST; GLUTATHIONE; LAZAROID; MONOCLONAL ANTIBODY; NIMODIPINE; NITRIC OXIDE SYNTHASE INHIBITOR; PROPOFOL; REACTIVE OXYGEN METABOLITE; TIRILAZAD;

DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAPEFRUIT JUICE; HYPERBARIC OXYGEN; ISCHEMIA; LIPID PEROXIDATION; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PLASMA; PROTEIN ANALYSIS; REPERFUSION INJURY; REVIEW; URINALYSIS;

EID: 13444283661     PISSN: 14793261     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1476-4431.2004.04005.x     Document Type: Review

References (122)

1. Heinecke JW. Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis. Atherosclerosis 1998; 141:1-15.
2. Moore K, Roberts LJ. Measurement of lipid peroxidation. Free Radic Res 1998; 28:659-671.
3. Kelly FJ. Urinary F2-isoprostane metabolite analysis: a step closer to obtaining a reliable measure of oxidative stress? Clin Exp Allergy 2001; 31:355-356.
4. Pratico D, Barry OP, Lawson JA, et al. IPF2alpha-I: an index of lipid peroxidation in humans. Proc Natl Acad Sci USA 1998; 95:3449-3454.
5. Morrow JD. The isoprostanes: their quantification as an index of oxidant stress status in vivo. Drug Metab Rev 2000; 32:377-385.
6. Ondiveeran HK, Fox-Robichaud A. New developments in the treatment of ischemia/reperfusion injury. Curr Opin Invest Drugs 2001; 2:783-791.
7. Meagher EA, FitzGerald GA. Indices of lipid peroxidation in vivo: strengths and limitations. Free Radic Biol Med 2000; 28:1745-1750.
8. Buege JA, Aust SD. Microsomal lipid peroxidation, In: Fleishers S, Packer L. eds. Biomembranes. New York: Academic Press; 1978, pp. 302-310.
9. Esterbauer H. Estimation of peroxidative damage. A critical review. Pathol Biol (Paris) 1996; 44:25-28.
10. Halliwell B, Grootveld M. The measurement of free radical reactions in humans. Some thoughts for future experimentation. FEBS Lett 1987; 213:9-14.
11. McMillan RM, MacIntyre DE, Booth A, et al. Malonaldehyde formation in intact platelets is catalysed by thromboxane synthase. Biochem J 1978; 176:595-598.
12. Yeo HC, Helbock HJ, Chyu DW, et al. Assay of malondialdehyde in biological fluids by gas chromatography-mass spectrometry. Anal Biochem 1994; 220:391-396.
13. Halliwell B, Gutteridge JM, Pryor W, et al. Lipid peroxidation: a radical chain reaction - measurement of lipid peroxidation, In: Halliwell B, Gutteridge JM. eds. Free Radicals in Biology and Medicine. Oxford: Oxford University Press/Clarendon Press; 1989, pp. 188-276.
14. Harrison KA, Murphy RC. Isoleukotrienes are biologically active free radical products of lipid peroxidation. J Biol Chem 1995; 270:17273-17278.
15. Morrow JD, Roberts LJ. The isoprostanes: unique bioactive products of lipid peroxidation. Prog Lipid Res 1997; 36:1-21.
16. Pratico D, Lawson JA, FitzGerald GA. Cyclooxygenase-dependent formation of the isoprostane, 8-epi prostaglandin F2 alpha. J Biol Chem 1995; 270:9800-9808.
17. Lawson JA, Li H, Rokach J, et al. Identification of two major F2 isoprostanes, 8,12-iso- and 5-epi-8, 12-iso-isoprostane F2alpha-VI, in human urine. J Biol Chem 1998; 273:29295-29301.
18. Longmire AW, Swift LL, Roberts LJ, et al. Effect of oxygen tension on the generation of F2-isoprostanes and malondialdehyde in peroxidizing rat liver microsomes. Biochem Pharmacol 1994; 47:1173-1177.
19. Morrow JD, Roberts LJ. Mass spectrometric quantification of F2-isoprostanes as indicators of oxidant stress, In: Armstrong D. ed. Oxidative Stress Biomarkers and Antioxidant Protocols. Totowa: Humana Press; 2002, pp. 57-66.
20. Roberts LJ, Morrow JD. The generation and actions of isoprostanes. Biochim Biophys Acta 1997; 1345:121-135.
21. Reilly M, Delanty N, Lawson JA, et al. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation 1996; 94:19-25.
22. Morrow JD, Roberts LJ. Mass spectrometry of prostanoids: F2-isoprostanes produced by non-cyclooxygenase free radical-catalyzed mechanism. Methods Enzymol 1994; 233:163-174.
23. Burke A, Lawson JA, Meagher EA, et al. Specific analysis in plasma and urine of 2,3-dinor-5, 6-dihydro-isoprostane F(2alpha)-III, a metabolite of isoprostane F(2alpha)-III and an oxidation product of gamma-linolenic acid. J Biol Chem 2000; 275:2499-2504.
24. Hinchcliff KW, Reinhart GA, DiSilvestro R, et al. Oxidant stress in sled dogs subjected to repetitive endurance exercise. Am J Vet Res 2000; 61:512-517.
25. Pratico D, Reilly M, Lawson J, et al. Formation of 8-iso-prostaglandin F2 alpha by human platelets. Agents Actions 1995; 45(Suppl.):27-31.
26. Morrow JD, Minton TA, Mukundan CR, et al. Free radical-induced generation of isoprostanes in vivo. Evidence for the formation of D-ring and E-ring isoprostanes. J Biol Chem 1994; 269:4317-4326.
27. Patrignani P, Santini G, Panara MR, et al. Induction of prostaglandin endoperoxide synthase-2 in human monocytes associated with cyclo-oxygenase- dependent F2-isoprostane formation. Br J Pharmacol 1996; 118:1285-1293.
28. McMichael M, Ruaux C, Baltzer W, et al. Elevated F2-alpha-isoprostane concentrations in the urine of dogs with intervertebral disc disease. In: Hughes D, ed. Proceedings of the 9th International VECC Symposium, 9-13 September 2003. San Antonio, TX: International Veterinary Emergency and Critical Care Society; 2003.
29. Humad S, Zarling E, Clapper M, et al. Breath pentane excretion as a marker of disease activity in rheumatoid arthritis. Free Radic Res Commun 1988; 5:101-106.
30. Weitz ZW, Birnbaum AJ, Sobotka PA, et al. High breath pentane concentrations during acute myocardial infarction. Lancet 1991; 337:933-935.
31. Morita S, Snider MT, Inada Y. Increased N-pentane excretion in humans: a consequence of pulmonary oxygen exposure. Anesthesiology 1986; 64:730-733.
32. Reiter R, Burk RF. Effect of oxygen tension on the generation of alkanes and malondialdehyde by peroxidizing rat liver microsomes. Biochem Pharmacol 1987; 36:925-929.
33. Drury JA, Nycyk JA, Cooke RW. Pentane measurement in ventilated infants using a commercially available system. Free Radic Biol Med 1997; 22:895-900.
34. Mendis S, Sobotka PA, Euler DE. Pentane and isoprene in expired air from humans: gas-chromatographic analysis of single breath. Clin Chem 1994; 40:1485-1488.
35. Allerheiligen SR, Ludden TM, Burk RF. The pharmacokinetics of pentane, a by-product of lipid peroxidation. Drug Metab Dispos 1987; 15:794-800.
36. Brisson BA, Miller CW, Chen G, et al. Effects of adenosine pretreatment on detection of free radicals in ischemic and reperfused canine gracilis muscle flaps by use of spin-trapping electron paramagnetic resonance spectroscopy. Am J Vet Res 2002; 63:175-180.
37. Brisson BA, Miller CW, Chen G, et al. Detection of free radicals in ischemic and reperfused canine gracilis muscle flaps by use of spin-trapping electron paramagnetic resonance spectroscopy. Am J Vet Res 2001; 62:384-388.
38. Center SA, Warner KL, Erb HN. Liver glutathione concentrations in dogs and cats with naturally occurring liver disease. Am J Vet Res 2002; 63:1187-1197.
39. Mathews WR, Guido DM, Fisher MA, et al. Lipid peroxidation as molecular mechanism of liver cell injury during reperfusion after ischemia. Free Radic Biol Med 1994; 16:763-770.
40. Reiter R, Wendel A. Chemically-induced glutathione depletion and lipid peroxidation. Chem Biol Interact 1982; 40:365-374.
41. Baskin CR, Hinchcliff KW, DiSilvestro RA, et al. Effects of dietary antioxidant supplementation on oxidative damage and resistance to oxidative damage during prolonged exercise in sled dogs. Am J Vet Res 2000; 61:886-891.
42. Szabo G, Bahrle S, Fazekas L, et al. Endothelin-A receptor antagonist BQ123 protects against myocardial and endothelial reperfusion injury. Thorac Cardiovasc Surg 1998; 46:232-236.
43. Harada K, Sugaya T, Murakami K, et al. Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. Circulation 1999; 100:2093-2099.
44. Javadov SA, Lim KH, Kerr PM, et al. Protection of hearts from reperfusion injury by propofol is associated with inhibition of the mitochondrial permeability transition. Cardiovasc Res 2000; 45:360-369.
45. Sato M, Ray PS, Maulik G, et al. Myocardial protection with red wine extract. J Cardiovasc Pharmacol 2000; 35:263-268.
46. Buras JA, Stahl GL, Svoboda KK, et al. Hyperbaric oxygen downregulates ICAM-1 expression induced by hypoxia and hypoglycemia: the role of NOS. Am J Physiol Cell Physiol 2000; 278:C292-C302.
47. Grisham MB, Granger DN, Lefer DJ. Modulation of leukocyte-endothelial interactions by reactive metabolites of oxygen and nitrogen: relevance to ischemic heart disease. Free Radic Biol Med 1998; 25:404-433.
48. Garden DL, Smith JK, Korthuis RJ. Neutrophil-mediated microvascular dysfunction in postischemic canine skeletal muscle. Role of granulocyte adherence. Circ Res 1990; 66:1436-1444.
49. Pearl JM, Drinkwater DC, Laks H, et al. Leukocyte-depleted reperfusion of transplanted human hearts: a randomized, double-blind clinical trial. J Heart Lung Transplant 1992; 11:1082-1092.
50. Moore TM, Khimenko P, Adkins WK, et al. Adhesion molecules contribute to ischemia and reperfusion-induced injury in the isolated rat lung. J Appl Physiol 1995; 78:2245-2252.
51. Martinez-Mier G, Toledo-Pereyra LH, McDuffie E, et al. L-selectin and chemokine response after liver ischemia and reperfusion. J Surg Res 2000; 93:156-162.
52. Rabb H, Mendiola CC, Saba SR, et al. Antibodies to ICAM-1 protect kidneys in severe ischemic reperfusion injury. Biochem Biophys Res Commun 1995; 211:67-73.
53. Wilkins PA, Ducharme NG, Lowe JE, et al. Measurements of blood flow and xanthine oxidase activity during postischemic reperfusion of the large colon of ponies. Am J Vet Res 1994; 55:1168-1177.
54. Shandall AA, Williams GT, Hallett MB, et al. Colonic healing: a role for polymorphonuclear leucocytes and oxygen radical production. Br J Surg 1986; 73:225-228.
55. Horton JW, White DJ. Cardiac contractile injury after intestinal ischemia-reperfusion. Am J Physiol 1991; 261:H1164-H1170.
56. Verma S, Fedak PW, Weisel RD, et al. Fundamentals of reperfusion injury for the clinical cardiologist. Circulation 2002; 105:2332-2336.
57. Marubayashi S, Oshiro Y, Maeda T, et al. Protective effect of monoclonal antibodies to adhesion molecules on rat liver ischemia-reperfusion injury. Surgery 1997; 122:45-52.
58. Granger DN, Kvietys PR, Perry MA. Leukocyte-endothelial cell adhesion induced by ischemia and reperfusion. Can J Physiol Pharmacol 1993; 71:67-75.
59. Harlan JM, Winn RK. Leukocyte-endothelial interactions: clinical trials of anti-adhesion therapy. Crit Care Med 2002; 30:5214-5219.
60. Cornejo CJ, Winn RK, Harlan JM. Anti-adhesion therapy. Adv Pharmacol 1997; 39:99-142.
61. Haug CE, Colvin RB, Delmonico FL, et al. A phase I trial of immunosuppression with anti-ICAM-1 (CD54) mAb in renal allograft recipients. Transplantation 1993; 55:766-772.
62. Kavanaugh AF, Davis LS, Jain RI, et al. A phase I/II open label study of the safety and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis. J Rheumatol 1996; 23:1338-1344.
63. Dove A. CD18 trials disappoint again. Nat Biotechnol 2000; 18:817-818.
64. Vedder NB, Harlan JM, Winn RK, et al. Immunomodulators: inhibitors of adhesion. Shock 2000; 13(Suppl. 1):1.
65. Rhee P, Morris J, Durham R, et al. Recombinant humanized monoclonal antibody against CD18 (rhuMAb CD18) in traumatic hemorrhagic shock: results of a phase II clinical trial. Traumatic Shock Group. J Trauma 2000; 49:611-619.
66. Sciuto AM. Antioxidant properties of glutathione and its role in tissue protection, In: Baskin S, Salem H. eds. Oxidants, Antioxidants, and Free Radicals. Washington, DC: Taylor & Francis; 1997, pp. 171-191.
67. Sies H, Brigelius R, Akerboom T. Intrahepatic glutathione status, In: Larsson A. ed. Function of Glutathione: Biochemical, Physiological, Toxicological, and Clinical Aspects. New York: Raven Press; 1983, pp. 51-65.
68. Kaplowitz N, Aw TY, Ookhtens M. The regulation of hepatic glutathione. Annu Rev Pharmacol Toxicol 1985; 25:715-744.
69. Marino P. The threat of oxidant injury, In: Marino P. ed. The ICU Book. Baltimore, MD: Williams & Wilkins; 1998, pp. 32-50.
70. Scott BC, Aruoma OI, Evans PJ, et al. Lipoic and dihydrolipoic acids as antioxidants. A critical evaluation. Free Radic Res 1994; 20:119-133.
71. Moldeus P, Cotgreave IA, Berggren M. Lung protection by a thiol-containing antioxidant: N-acetylcysteine. Respiration 1986; 50(Suppl. 1):31-42.
72. Bernard GR, Lucht WD, Niedermeyer ME, et al. Effect of N-acetylcysteine on the pulmonary response to endotoxin in the awake sheep and upon in vitro granulocyte function. J Clin Invest 1984; 73:1772-1784.
73. Revesz L, Malaise E. Significance of cellular glutathione in radioprotection and repair of radiation damage, In: Larsson A. ed. Function of Glutathione: Biochemical, Physiological, Toxicological, and Clinical Aspects. New York: Raven Press; 1983, pp. 163-173.
74. Sciuto AM, Strickland PT, Kennedy TP, et al. Protective effects of N-acetylcysteine treatment after phosgene exposure in rabbits. Am J Respir Crit Care Med 1995; 151:768-772.
75. Carroll JE, Howard EF, Hess DC, et al. Nuclear factor-kappa B activation during cerebral reperfusion: effect of attenuation with N-acetylcysteine treatment. Brain Res Mol Brain Res 1998; 56:186-191.
76. Ferrari R, Ceconi C, Curello S, et al. Oxygen free radicals and myocardial damage: protective role of thiol-containing agents. Am J Med 1991; 91:95S-105S.
77. Henderson A, Hayes P. Acetylcysteine as a cytoprotective antioxidant in patients with severe sepsis: potential new use for an old drug. Ann Pharmacother 1994; 28:1086-1088.
78. Suter PM, Domenighetti G, Schaller MD, et al. N-acetylcysteine enhances recovery from acute lung injury in man. A randomized, double-blind, placebo-controlled clinical study. Chest 1994; 105:190-194.
79. Halliwell B, Gutteridge JM. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol 1990; 186:1-85.
80. Heitzer T, Just H, Munzel T. Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation 1996; 94:6-9.
81. Heitzer T, Schlinzig T, Krohn K, et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104:2673-2678.
82. Ernster L. Lipid peroxidation in biological membranes: mechanisms and implications, In: Yogi K. ed. Active Oxygen, Lipid Peroxides, and Antioxidants. Boca Raton, FL/Tokyo: CRC Press/Japan Scientific Societies Press; 1993, pp. 1-38.
83. Meyer FB, Anderson RE, Yaksh TL, et al. Effect of nimodipine on intracellular brain pH, cortical blood flow, and EEG in experimental focal cerebral ischemia. J Neurosurg 1986; 64:617-626.
84. Gunn AJ, Mydlar T, Bennet L, et al. The neuroprotective actions of a calcium channel antagonist, flunarizine, in the infant rat. Pediatr Res 1989; 25:573-576.
85. Levene MI, Gibson NA, Fenton AC, et al. The use of a calcium-channel blocker, nicardipine, for severely asphyxiated newborn infants. Dev Med Child Neurol 1990; 32:567-574.
86. Watts JA, Hawes EM, Jenkins SH, et al. Effects of nisoldipine on the no-reflow phenomenon in globally ischemic rat hearts. J Cardiovasc Pharmacol 1990; 16:487-494.
87. Villari B, Ambrosio G, Golino P, et al. The effects of calcium channel antagonist treatment and oxygen radical scavenging on infarct size and the no-reflow phenomenon in reperfused hearts. Am Heart J 1993; 125:11-23.
88. Taniyama Y, Ito H, Iwakura K, et al. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol 1997; 30:1193-1199.
89. Granger DN. Role of xanthine oxidase and granulocytes in ischemia-reperfusion injury. Am J Physiol 1988; 255:H1269-H1275.
90. Grisham MB, Hernandez LA, Granger DN. Xanthine oxidase and neutrophil infiltration in intestinal ischemia. Am J Physiol 1986; 251:G567-G574.
91. Granger DN, Benoit JN, Suzuki M, et al. Leukocyte adherence to venular endothelium during ischemia-reperfusion. Am J Physiol 1989; 257:G683-G688.
92. Toledo-Pereyra LH, Simmons RL, Najarian JS. Effect of allopurinol on the preservation of ischemic kidneys perfused with plasma or plasma substitutes. Ann Surg 1974; 180:780-782.
93. Moorhouse PC, Grootveld M, Halliwell B, et al. Allopurinol and oxypurinol are hydroxyl radical scavengers. FEBS Lett 1987; 213:23-28.
94. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362:59-62.
95. O'Farrell D, Chen LE, Seaber AV, et al. Efficacy of recombinant human manganese superoxide dismutase compared to allopurinol in protection of ischemic skeletal muscle against 'no-reflow'. J Reconstr Microsurg 1995; 11:207-214.
96. Kondo S, Segawa T, Tanaka K, et al. Mannosylated superoxide dismutase inhibits hepatic reperfusion injury in rats. J Surg Res 1996; 60:36-40.
97. Land W, Schneeberger H, Schleibner S, et al. The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants. Transplantation 1994; 57:211-217.
98. Negita M, Ishii T, Kunikata S, et al. Prevention of posttransplant acute tubular necrosis in kidney graft by perioperative superoxide dismutase infusion. Transplant Proc 1994; 26:2123-2124.
99. Zimmerman BJ, Grisham MB, Granger DN. Role of oxidants in ischemia/reperfusion-induced granulocyte infiltration. Am J Physiol 1990; 258:G185-G190.
100. Jolly SR, Kane WJ, Bailie MB, et al. Canine myocardial reperfusion injury. Its reduction by the combined administration of superoxide dismutase and catalase. Circ Res 1984; 54:277-285.
101. Shlafer M, Kane PF, Kirsh MM. Superoxide dismutase plus catalase enhances the efficacy of hypothermic cardioplegia to protect the globally ischemic, reperfused heart. J Thorac Cardiovasc Surg 1982; 83:830-839.
102. Galey JB. Recent advances in the design of iron chelators against oxidative damage. Mini Rev Med Chem 2001; 1:233-242.
103. Menasche P, Antebi H, Alcindor LG, et al. Iron chelation by deferoxamine inhibits lipid peroxidation during cardiopulmonary bypass in humans. Circulation 1990; 82:IV390-IV396.
104. Haraldsson G, Sorensen V, Nilsson U, et al. Effect of pre-treatment with desferrioxamine and mannitol on radical production and kidney function after ischaemia-reperfusion. A study on rabbit kidneys. Acta Physiol Scand 1995; 154:461-468.
105. Amersi F, Dulkanchainun T, Nelson SK, et al. A novel iron chelator in combination with a P-selectin antagonist prevents ischemia/reperfusion injury in a rat liver model. Transplantation 2001; 71:112-118.
106. Lantz GC, Badylak SF, Hiles MC, et al. Treatment of reperfusion injury in dogs with experimentally induced gastric dilatation-volvulus. Am J Vet Res 1992; 53:1594-1598.
107. deLemos RA, Roberts RJ, Coalson JJ, et al. Toxic effects associated with the administration of deferoxamine in the premature baboon with hyaline membrane disease. Am J Dis Child 1990; 144:915-919.
108. Hammerman C, Kaplan M. Ischemia and reperfusion injury. The ultimate pathophysiologic paradox. Clin Perinatol 1998; 25:757-777.
109. Sekizuka E, Benoit JN, Grisham MB, et al. Dimethylsulfoxide prevents chemoattractant-induced leukocyte adherence. Am J Physiol 1989; 256:H594-H597.
110. Parks DA, Shah AK, Granger DN. Oxygen radicals: effects on intestinal vascular permeability. Am J Physiol 1984; 247:G167-G170.
111. Arden WA, Slocombe RF, Stick JA, et al. Morphologic and ultrastructural evaluation of effect of ischemia and dimethyl sulfoxide on equine jejunum. Am J Vet Res 1990; 51:1784-1791.
112. Horne MM, Pascoe PJ, Ducharme NG, et al. Attempts to modify reperfusion injury of equine jejunal mucosa using dimethylsulfoxide, allopurinol, and intraluminal oxygen. Vet Surg 1994; 23:241-249.
113. Schiller HJ, Reilly PM, Bulkley GB. Tissue perfusion in critical illnesses. Antioxidant therapy. Crit Care Med 1993; 21:592-5102.
114. Badylak SF, Lantz GC, Jeffries M. Prevention of reperfusion injury in surgically induced gastric dilatation-volvulus in dogs. Am J Vet Res 1990; 51:294-299.
115. Garcia-Criado FJ, Eleno N, Santos-Benito F, et al. Protective effect of exogenous nitric oxide on the renal function and inflammatory response in a model of ischemia-reperfusion. Transplantation 1998; 66:982-990.
116. Roza AM, Cooper M, Pieper G, et al. NOX 100, a nitric oxide scavenger, enhances cardiac allograft survival and promotes long-term graft acceptance. Transplantation 2000; 69:227-231.
117. Pang CY, Neligan P, Zhong A, et al. Effector mechanism of adenosine in acute ischemic preconditioning of skeletal muscle against infarction. Am J Physiol 1997; 273:R887-R895.
118. Cronstein BN, Rosenstein ED, Kramer SB, et al. Adenosine; a physiologic modulator of superoxide anion generation by human neutrophils. Adenosine acts via an A2 receptor on human neutrophils. J Immunol 1985; 135:1366-1371.
119. Grisham MB, Hernandez LA, Granger DN. Adenosine inhibits ischemia-reperfusion-induced leukocyte adherence and extravasation. Am J Physiol 1989; 257:H1334-H1339.
120. Sakata C, Tanaka H, Takemura S, et al. Post-ischemic intraportal adenosine administration protects against reperfusion injury of canine liver. J Hepatobiliary Pancreat Surg 2000; 7:78-85.
121. Peralta C, Hotter G, Closa D, et al. The protective role of adenosine in inducing nitric oxide synthesis in rat liver ischemia preconditioning is mediated by activation of adenosine A2 receptors. Hepatology 1999; 29:126-132.
122. Rupprecht HJ, vom DJ, Terres W, et al. Cardioprotective effects of the Na(+)/H(+) exchange inhibitor cariporide in patients with acute anterior myocardial infarction undergoing direct PTCA. Circulation 2000; 101:2902-2908.